Dharam Ablashi Research Fund – Pilot Grant Program

The Dharam Ablashi Research Fund Pilot Grants are designed to generate data that could be used to develop a larger grant proposal.

The deadlines for 2017 are January 31st, March 31st, August 31st and December 29th.

Although the Foundation is interested in supporting quality projects in all research relating to HHV-6, areas of special interest include:

  • Biopsy studies by IHC and PCR
  • HHV-6 & autoimmunity
  • HHV-6 latency
  • HHV-6 & mitochondrial disease
  • HHV-6 reactivation & fatigue
  • Antiviral testing of novel compounds
  • Novel assays
  • CNS disease associations
  • Chromosomally Integrated HHV-6
  • HHV-6B & acute GVHD
  • HHV-6 in heart disease
  • HHV-6 as a trigger for malignancy

Projects that are simply extensions of ongoing research or that already have ample supporting data will not be considered.

Dharam Ablashi, Scientific Director of the HHV-6 Foundation

Application Procedure

Proposals should be brief, with the project description strictly limited to six pages.  Applications may be submitted at any time during the year, and they are peer-reviewed quickly, with a response within 30 to 60 days. Please describe in detail the proposed economics of the study (e.g. costs for reagents, labor, equipment, indirect costs, etc.)

Applicants must first complete our form by following this link.

After submitting the previous form, applicants must send several required attachments to our email. Please use PDF or DOC/DOCX file formats. Please use this email link to send the attachments below.

  • Cover Letter (No page limit, within reason)
  • Curriculum Vitae
  • Grant Proposal (6 pages maximum, including budget)
  • (Optional) Supplementary Material

Peer Review & Assistance

Proposals will be evaluated by the HHV-6 Foundation’s Scientific Advisory Board, plus selected outside experts, under the direction of the Scientific Director. See Scientific Advisory Board. The Scientific Director and associated experts are also available for ongoing advice once the project has begun and for pre-application assistance.

Eligibility & Conditions

These grants are available to investigators at established research institutions.  Grants are available to citizens of any country.

Funding for Pilot Research Projects is limited to a maximum of $25,000 in direct costs for one year. The Foundation will not fund major items of equipment, salary for principal investigator or extensive travel. The Foundation may add an amount for indirect costs up to 10% of the sum requested by the principal investigator to be paid to the investigator’s institution.

At the termination of the Pilot Research project, the investigator is asked to prepare a detailed report of the findings and account for the expenditures within 30 days.


If a manuscript is accepted for publication, the investigator is asked to acknowledge the HHV-6 Foundation’s support with a sentence such as “This investigation was supported by a Dharam Ablashi Research Fund Grant from the HHV-6 Foundation.”  We also ask that an advance copy of the manuscript be sent by email to the HHV-6 Foundation’s Scientific Director, after acceptance but before publication.

Studies funded by the HHV-6 Foundation

Human herpesvirus 6B induced hypomethylation on chromosome 17p13.3 Elin Enghdahl, Karolinska Institute
HHV-6 infection in patients after allogeneic HSCT Raffaella Greco, MD, San Raffaele Scientific Institute, Milano, Italy
ciHHV-6 activation in response to drugs Bhupesh Prusty, PhD, University of Würzburg
Chromosomal integration in HSCT patients Vicki Boussiotis, MD. PhD, Beth Israel Deasoness Medical Center
HHV-6 in Gliomas Nanjing Medical University
Exploration of ciHHV6 in the Generation Scotland dataset Ruth Jarrett, University of Glasgow
HHV-6 in Post Transplant Limbic Encephalitis Joshua Hill, Fred Hutchinson Cancer Research Center
Detection of HHV-6 in Children with Epilepsy Tobias Loddenkemper, MD, Boston Children’s Hospital
HHV-6A genomic integration in Zambia and infant development Gompels, London School of Hygiene & Tropical Medicine
HHV-6 infection and ciHHV-6 in cord blood transplantation Anoma Nellore, Beth Israel Deaconness Medical Center
HHV-6 and parvovirus B19 co-infection in a wide variety of human diseases and cancer Jacqueline Hobbs, University of Florida College of Medicine
HHV-6 genomic integration in Zambia and infant development Ursula Gompels, University of London School of Hygiene and Tropical Medicine
HHV-6 in Hodgkin’s Lymphoma Ruth Jarrett, University of Glasgow Center for Virus Research
Efficacy of antiviral drug treatment of HHV-6 infection Peter Medveczky, University of South Florida
Development of Humanized Rag2-/-gc-/- Mice as a model of HHV-6A infection Bradford Berges, Brigham Young University
The contribution of neuroinflammatory responses to HHV-6B/HHV-7 infection in the pathogenesis of mesial temporal lobe epilepsy Jin Mei Li & Dong Zhou, West China Hospital & Sichuan University
HHV-6 in adult and pediatric brain tumors Michael Scheurer, Dan L. Duncan and Texas Children’s Cancer Centers, Baylor College of Medicine
Prevalence and significance of ciHHV-6 infection in liver transplant recipients Raymund Razonable, Division of Transplant and Infectious Diseases, Mayo Clinic
Study of Chromosomally Integrated HHV-6 Subjects Prior and Post Valcyte Treatment Daniel Peterson, Simmaron Research
The role of HHV-6 in pediatric convulsions of unknown cause Ankrah Lennox-Mac, Department of Microbiology, University of Ghana Medical School
Development of an improved TCID50 assay for HHV-6A Rasmus Gustafsson, The Karolinska Institute, Sweden
Human Herpesvirus-6, dendritic cells and TH17 Anshu Agrawal, University of California at Irvine
The role of U94/rep gene and TTAGGG telometric repeats of HHV-6 in integration in human chromosomes Peter Medveczky, University of South Florida
The Functional Characterization of HHV-6/U94 Gene Product Louis Flamand, Centre Hospital University de Quebec
Anti-HHV-6 activity of the broad antiinfective drug artesunate: investigation of the mode of action Jens Milbradt & Manfred Marschall, Institute for Clinical and Molecular Virology, Erlangen Medical Center, Germany
Adoptive T cell Immunotherapy to Prevent or Treat HHV-6 Ulrike Gerdeman, Center for Cell & Gene Therapy, Baylor University
XMRV, HHV-6, EBV & Endogenous retroviruses in patients with CFS Brigitte Huber, Tufts University
2008 and Beyond
HHV-6 Specific CD8+ T cell Responses Sudhir Gupta, MD, PhD, MACP University of California Irvine, California USA
Development of a Variant-specific, Calibrated Real-time PCR Assay for the Absolute Quantification of HHV-6A and B Nucleic Acids in Clinical Samples Mauro S. Malnati, MDSan Raffaele Scientific InstituteMilan, Italy USA
The Human Herpesvirus 6A U45 Gene Product: Role in Immune Dysfunction Marshall Williams, PhDOhio State University, USA
Variant Specific PCR ELISA Yi-Wei Tang, MD, PhDVanderbilt University, USA
Determination of the chromosomal integration of the HHV-6 virus in highly seropositive Chronic Fatigue Syndrome patients Daniel L. Peterson, MD, Sierra Internal Medicine, Nevada, USA
The role of chronic immune stimulation by active herpesvirus 6 (HHV-6) infection/coinfections in immune dysfunction and development of lymphoma Daniel L. Peterson, MD, Sierra Internal Medicine, Nevada, USA
Investigation of inhibitory effects of the multipotent drug Artesunate against HHV-6 Manfred Marschall, PhDUniversität Erlangen-Nürnberg, Germany
Creation of a humanized CD46 mouse model for HHV-6 infection Claude P. Genain, MDCalifornia Pacific Medical Center Research Institute, San Francisco USA
Study of HHV-6 & EBV in patients with CNS Dysfunction and long-standing fatigue Jose Montoya, MDStanford University, USA
Use of recombinant viral proteins for the identification of active HHV-6 infection by serological assays. Louis Flamand, PhD,Universite Laval, Quebec, Canada, USA
Cloning the HHV-6 A and B genome for the identification of genes responsible for pathogenicity Peter Medveczky, MD, University of South Florida, College of Medicine, USA
A study of incidence of ciHHV-6 in children with congenital infection of HHV-6 Carolyn Hall, MDUniversity of Rochester
Study of HHV-6B in Mesial Temporal Lobe Epilepsy Nihal De Lanerolle, MD, PhDYale University, MD, PhD
ciHHV-6 FISH analysis Peter Ambros, PhDChildren’s Cancer Research Institute
HHV-6 activation of HERV K18 Brigitte Huber, PhdTufts University